Navigo Proteins Gmbh

Repligen Corporation

Basf Se Corporation

Bayer Intellectual Property Gmbh

Ulrich Haupts

Erik Fiedler

Andreas Scheidig

Eva Bosse-Doenecke

Maren Meysing

Paul Knick

Birgitta Leuthner

Uwe Gritzan

Michael Strerath

Oliver Kensch

Christian Votsmeier

Wayne Coco

Peter Scholz

Susanne Steinig

Manja Gloser

Hanna Plittersdorf

Simone Brueckner

Nadine Koch

Wayne M Coco

Kornelia Kirchner

Kerstin Baral

Anja Katzschmann

Madlen Zwarg

Ute Beister

Florian Settele

Markus Liebscher

Mathias Kahl

Jan Tebe

Hanna Bobolowski

Manja Gloser-Bräunig

Markus Rarbach

Ulrich Kettling

Klaus Pellengahr

The present invention relates to Fc binding proteins comprising one or more domains with Cysteine in the C-terminal helical region. The invention further relates to affinity matrices comprising the Fc binding proteins of the invention. The invention also relates to a use of these Fc binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Fc binding proteins of the invention.

Fc binding proteins with cysteine in the C-terminal helical region

Fc binding proteins with cysteine in the c-terminal helical region

The invention generally relates to targeted compounds for the site-specific coupling of chemical moieties. The present invention features a targeted compound for the coupling of chemical moieties comprising at least one targeting domain capable of binding a target, and at least one linking moiety of up to 80 amino acids, preferably alanine, proline, and serine, and at least one coupling site consisting of cysteine or a cysteine-rich peptide motif (CXC, CXXC, or CXXXC), and wherein said linking moiety connects the targeting domain and a coupling site and/or wherein a linking moiety connects two coupling sites. The invention further features fusion proteins with ubiquitin muteins (Affilin @) as targeting domain. The invention also relates to the use of the targeted compounds for medical applications, in treatment or diagnosis of diseases.

Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker

The invention relates to fusion proteins comprising at least one extradomain B of fibronectin (ED-B) specific binding domain with high stability in serum and at least one APS domain essentially consisting of or consisting of up to about 80 amino acids selected from alanine, proline, serine, and optionally aspartic acid. The fusion protein further comprises at least one coupling site consisting of at least one cysteine. The invention relates to the use of the fusion proteins or of compositions comprising the fusion proteins for medical applications, such as diagnosis or treatment of cancer or cardiovascular diseases.

Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer

The present invention relates to immunoglobulin (Ig) binding proteins comprising one or more Ig binding domains with amino acids selected from the group consisting at least of 1I, 11A, 11E, 11I, 35R, 35I, and 42L. The invention further relates to affinity matrices comprising the Ig binding proteins of the invention. The invention also relates to a use of these Ig binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Ig binding proteins of the invention.

Alkaline stable immunoglobulin-binding proteins

Provided are populations of polypeptides, wherein each member of the population of polypeptides includes or is an amino sequence as set forth in SEQ ID NO: 5 or SEQ ID NO: 6. Also provided are methods for identifying polypeptides that bind to pre-selected target molecules, which in some embodiments can include providing a population of polypeptides as described herein, contacting the population of polypeptides with a pre-selected target molecule, and identifying a complex comprising at least one member of the population of polypeptides bound to the pre-selected target molecule; and populations of nucleic acid molecules that encode the presently disclosed populations of polypeptides.

Populations of polypeptides having a triple-helical structure

The present invention relates to Fc binding proteins comprising one or more Fc binding domains wherein at least one domain comprises of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-6 or 21. The invention further relates to affinity matrices comprising the Fc binding proteins of the invention. The invention also relates to a use of these Fc binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Fc binding proteins of the invention.

Alkaline stable Fc-binding proteins for affinity chromatography

The present invention relates to new EGFR binding molecules based on ubiquitin muteins (Affilin&#xae;), preferably Affilin molecules having a characteristic three amino acid residue motif. The invention further refers to EGFR binding molecules that bind to different or non-overlapping epitopes than the anti-EGFR monoclonal antibody Cetuximab. The invention further relates to the use of these EGFR binding proteins in medicine, preferably for use in the diagnosis or treatment of cancer.

EGFR binding proteins

The present disclosure relates to non-natural binding proteins comprising one or more non-natural immunoglobulin (Ig) binding domains wherein at least one non-natural lg-binding domain comprises the amino acid sequence X1 X2X3XiXsX5X7 XsQQX11AFYX1sX15LX1 sX19PX21 LX23X24X2sQRX28X2gf IQSLKDDPSXio SXi2Xi3Xi4LXi5EAXigKLXs2Xs3Xs4QXs5PX. The disclosure also relates to compositions such as affinity matrices comprising the non-natural Ig-binding proteins of the invention. Use of these Ig-binding proteins or of the compositions for affinity purification of immunoglobulins and to methods of affinity purification.

Immunoglobulin-binding proteins and their use in affinity purification

Growing community of inventors

Halle/Saale, Germany

Ulrich Haupts